GSK plc (NYSE:GSK) Shares Sold by Lincluden Management Ltd.

Lincluden Management Ltd. decreased its position in GSK plc (NYSE:GSK) by 61.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 65,975 shares of the pharmaceutical company’s stock after selling 103,772 shares during the quarter. Lincluden Management Ltd.’s holdings in GSK were worth $2,445,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Verdence Capital Advisors LLC lifted its holdings in shares of GSK by 7.0% in the 3rd quarter. Verdence Capital Advisors LLC now owns 7,237 shares of the pharmaceutical company’s stock worth $262,000 after purchasing an additional 473 shares during the last quarter. Advisor Partners II LLC boosted its holdings in shares of GSK by 20.6% during the third quarter. Advisor Partners II LLC now owns 27,956 shares of the pharmaceutical company’s stock valued at $1,013,000 after acquiring an additional 4,766 shares during the period. Park Avenue Securities LLC grew its position in shares of GSK by 8.5% during the third quarter. Park Avenue Securities LLC now owns 43,817 shares of the pharmaceutical company’s stock worth $1,588,000 after acquiring an additional 3,419 shares during the last quarter. Nordwand Advisors LLC acquired a new stake in shares of GSK in the 3rd quarter worth about $1,704,000. Finally, First Trust Direct Indexing L.P. lifted its position in GSK by 3.0% in the 3rd quarter. First Trust Direct Indexing L.P. now owns 13,246 shares of the pharmaceutical company’s stock valued at $480,000 after purchasing an additional 387 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Price Performance

NYSE:GSK traded up $0.40 during trading hours on Friday, reaching $45.07. 3,771,079 shares of the company’s stock were exchanged, compared to its average volume of 3,390,015. GSK plc has a 12 month low of $33.33 and a 12 month high of $45.10. The business’s 50-day simple moving average is $42.08 and its two-hundred day simple moving average is $39.43. The company has a market capitalization of $93.40 billion, a P/E ratio of 16.33, a price-to-earnings-growth ratio of 1.90 and a beta of 0.65. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.15.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be given a dividend of $0.3762 per share. The ex-dividend date of this dividend is Thursday, May 16th. This is a positive change from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.34%. GSK’s payout ratio is 57.61%.

Analysts Set New Price Targets

Several research firms have commented on GSK. Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Morgan Stanley started coverage on GSK in a research report on Tuesday, January 23rd. They issued an “equal weight” rating on the stock. Finally, Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, GSK currently has a consensus rating of “Moderate Buy”.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.